Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving luciferase
Reexamination Certificate
2005-04-26
2005-04-26
Spector, Lorraine (Department: 1646)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving luciferase
C435S007100, C435S007200, C530S350000, C536S023500
Reexamination Certificate
active
06884598
ABSTRACT:
The present invention provides methods for screening for a molecule that antagonizes or agonizes RANK activity. One aspect of the invention involves the growth of RANK responsive cells in semi-solid medium, wherein exposure to a RANK antagonist promotes colony formation. Other aspects of the invention rely on promoter/reporter constructs using RANK responsive promoters derived from the MMP-9 and TRAP genes. Additional aspects of the invention exploit the ability of RANK to activate c-src activity, F-actin ring formation and CaPO4resorption.
REFERENCES:
patent: 5843678 (1998-12-01), Boyle
patent: 6015938 (2000-01-01), Boyle et al.
patent: 6017729 (2000-01-01), Anderson et al.
patent: 6171860 (2001-01-01), Baker et al.
patent: 6242213 (2001-06-01), Anderson
patent: 6242586 (2001-06-01), Gorman et al.
patent: 6284485 (2001-09-01), Boyle et al.
patent: 6316408 (2001-11-01), Boyle
patent: 6369027 (2002-04-01), Boyle et al.
patent: 6410516 (2002-06-01), Baltimore et al.
patent: 6492124 (2002-12-01), Wong et al.
patent: 6537763 (2003-03-01), Dougall et al.
patent: 20020068690 (2002-06-01), Baldwin et al.
patent: 20020127637 (2002-09-01), Ni et al.
patent: 20020159970 (2002-10-01), Choi et al.
patent: 20030013170 (2002-12-01), Aggarwal et al.
patent: 20030013651 (2003-01-01), Lam et al.
patent: 0 418 014 (1995-12-01), None
patent: 0 873 998 (1998-10-01), None
patent: 0 911 342 (1999-04-01), None
patent: 1 087 230 (2001-03-01), None
patent: 11009269 (1999-01-01), None
patent: WO 9825958 (1998-06-01), None
patent: WO 9846751 (1998-10-01), None
patent: WO 9854201 (1998-12-01), None
patent: WO 9929865 (1999-06-01), None
patent: WO 0015807 (2000-03-01), None
patent: WO 0075185 (2000-12-01), None
patent: WO 0103719 (2001-01-01), None
patent: WO 0108677 (2001-02-01), None
patent: WO 0108699 (2001-02-01), None
patent: WO 0116299 (2001-03-01), None
patent: WO 0117543 (2001-03-01), None
patent: WO 0118203 (2001-03-01), None
patent: WO 0122090 (2001-03-01), None
patent: WO 0123549 (2001-04-01), None
patent: WO 0134827 (2001-05-01), None
patent: WO 0162932 (2001-08-01), None
patent: WO 0191793 (2001-12-01), None
patent: WO 0215846 (2002-02-01), None
patent: WO 0216551 (2002-02-01), None
patent: WO 02064782 (2002-08-01), None
patent: WO 02076507 (2002-10-01), None
patent: WO 02080955 (2002-10-01), None
patent: WO 02092623 (2002-11-01), None
patent: WO 02095012 (2002-11-01), None
patent: WO 03002713 (2003-12-01), None
Takahashi N et al., “A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function,”Biochem Biophys Res Commun1999; 256:449-455.
Tsukii K et al., “Osteoclast differentiation factor mediates an essential signal for bone resorption induced by 1α,25-dihydroxyvitamin D3, prostaglandin E2, or parathyroid hormone in the microenvironment of bone,”Biochem Biophys Res Commun1998; 246:337-341.
Childs L et al., “Safety and efficacy of RANK:Fc treatment for the prevention and amelioration of established osteolysis,” 2001, Orthopedic Research Society, San Francisco, Abstract.
Darnay BG et al., “Characterization of the intracellular domain of receptor activator of NF-κB (RANK),”J Biol ChemAug. 1998, 273(32):20551-20555.
Dougall W et al., “Rank is essential for osteoclast and lymph node development,”Genes Dev1999, 13:2412-2424.
Ducy P et al., “The osteoblast: a sophisticated fibroblast under central surveillance,”ScienceDec. 2000, 289:1501-1508.
Galibert L et al., “The involvement of multiple tumor necrosis factor receptor (TNFR)-associated factors in the signaling mechanisms of receptor activator of NF-κB, a member of the TNFR superfamily,”J Biol ChemDec. 1998, 273(51):34120-34127.
Hofbauer LC et al., “The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption,”J Bone Miner ResNov. 2000, 15:2-12.
Hsu H et al., “Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand,”Proc Natl Acad Sci USAMar. 1999;96:3540-3545.
Kodaira K et al., “Cloning and characterization of the gene encoding mouse osteoclast differentiation factor,”Gene1999, 230:121-127.
Lacey DL et al., “Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation,”Cell1998, 93:165-176.
Lakkakorpi P and Vaananen, “Kinetics of the osteoclast cytoskeleton during the resorption cycle in vitro,”J Bone Min Res1991, 6(8):817-826.
Lee ZH et al., “Activation of c-Jun N-terminal kinase and activator protein 1 by receptor activator of nuclear factor κB,”Mol Pharmacol2000, 58(6):1536-1545.
Lowe C et al., “Osteopetrosis in Src-deficient mice is due to an autonomous defect of osteoclasts,”Proc. Natl. Acad. Sci. USA1993, 91:4485-4489.
Nakagawa N et al., “RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis,”Biochem Biophys Res Commun1998, 253:395-400.
Oyajobi BO et al., “A soluble murine receptor activator of NF-κB-human immunoglobulin fusion protein (RANK.Fc) inhibits bone resorption in a murine model of human multiple myeloma bone disease,”J Bone Min ResSep. 2000, 15(suppl. 1):S176, Abstract #1151.
Oyajobi BO et al., “Therapeutic efficacy of a soluble receptor activator of nuclear factor κB-IgG Fc fusion protein in suppression bone resorption and hypercalcemia in a model of humoral hypercalcemia of malignancy,”Cancer ResMar. 2001, 61:2572-2578.
Pearse RN et al., “Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression,”PNASSep. 2001. 98:11581-11586.
Rodan GA and Martin TJ, “Therapeutic approaches to bone diseases,”ScienceSep. 2000, 289:1508-1514.
Roodman D, “Advances in bone biology: the osteoclast,”Endocr Rev1996, 17:308-332.
Sato H et al., “v-Src activates the expression of 92-kDa type IV collagenase gene through the AP-1 site and the GT box homologous to retinoblastoma control elements,”J Biol ChemNov. 1993, 268(31): 23460-23468.
Shevde NK et al., “Estrogen inhibits RANKL stimulated osteoclastogenesis in isolated murine myeloid progenitors and the monocytic/macrophagic cell line RAW 264.7,”J Bone Min Res1999, 14(suppl.1):5150.
Simonet WS et al., “Osteoprotegerin: a novel secreted protein involved in the regulation of bone density,”CellApr. 1997, 89:309-319.
Suda T et al., “Modulation of osteoclast differentiation,”Endocr RevFeb 1992, 13(2):66-80.
Takayanagi H et al., “Involvement of receptor activator of nuclear factor κB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis,”Arthritis RheumFeb. 2000, 43(2):259-269.
Wong BR et al., “The TRAF family of signal transducers mediates NF-κB activation by the TRANCE receptor,”J Biol ChemOct. 1998, 273(43):28355-28359.
Wong BR et al., “TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src,”Mol CellDec. 1999, 4:1041-1049.
Yasuda H et al., “Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL,”PNASMar. 1998, 95:3597-3602.
Immunex Corporation
O'Hara Eileen B.
Sheiness Diana K.
Spector Lorraine
LandOfFree
Screening assays for agonists and antagonists of receptor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Screening assays for agonists and antagonists of receptor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Screening assays for agonists and antagonists of receptor... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3395382